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Abstract
Detection of multiple human papillomavirus (HPV) types in the genital tract is common. Associations among HPV types may
impact HPV vaccination modeling and type replacement. The objectives were to determine the distribution of concurrent
HPV type infections in cervicovaginal samples and examine type-specific associations. We analyzed HPV genotyping results
from 32,245 cervicovaginal specimens collected from women aged 11 to 83 years in the United States from 2001 through
2011. Statistical power was enhanced by combining 6 separate studies. Expected concurrent infection frequencies from a
series of permutation models, each with increasing fidelity to the real data, were compared with the observed data.
Statistics were computed based on the distributional properties of the randomized data. Concurrent detection occurred
more than expected with 0 or $3 HPV types and less than expected with 1 and 2 types. Some women bear a
disproportionate burden of the HPV type prevalence. Type associations were observed that exceeded multiple hypothesis
corrected significance. Multiple HPV types were detected more frequently than expected by chance and associations
among particular HPV types were detected. However vaccine-targeted types were not specifically affected, supporting the
expectation that current bivalent/quadrivalent HPV vaccination will not result in type replacement with other high-risk
types.
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Introduction
Genital HPV is the most common sexually transmitted infection
[1,2]. HPV is a necessary, but not sufficient, cause of cervical
cancer [3,4] and genital warts [5] and is associated with other
anogenital cancers [6]. Of the over 100 HPV types, at least 40
infect the anogenital tract. Twelve types have evidence sufficient
for classification as ‘‘high-risk’’ HPV (HR HPV) and an additional
13 have some limited evidence of cancer risk [7]. Concurrent
infection with multiple HPV types is common, especially in young
women and in people with HIV infections [8–16]. Concurrent
infection with multiple HPV types compared to single HR-HPV
infection has been found to increase the risk of disease in some
reports [17,18] but not in others [4,15,19]. The high prevalence of
HPV and frequency of concurrent infections with more than one
type provides an opportunity for HPV type interactions.
The current HPV vaccines target the two HR-HPV types
(HPVs 16 and 18) associated with 70% of cervical cancers. If,
however, types display positive associations to inflate infection
rates, broad HPV vaccination coverage may lead to reduction of
HPV types not targeted by the vaccine, i.e. ‘‘cross-protection’’ not
based on cross-reaction immunity but as a result of reduced fitness
of positively associated types. Alternatively, negative associations
among types may lead to type replacement of non-vaccine types as
competing types targeted by vaccines are reduced [20].
Associations among multiple HPV types have been examined in
prior studies, but the conclusions are contradictory [21–28]. A
limiting factor for robust analysis of type associations is the
number of HPV positive samples in a dataset relative to the
hundreds of potential type combinations.
The aim of the present study is to address overall and type-
specific HPV associations by taking advantage of a large
laboratory database of HPV results obtained using the same
validated HPV typing assay. Aggregating multiple study datasets
provides greater statistical power in analyzing potential HPV type
combinations. We employed a permutation methodology to test
first a complete null model of random type association, and then




The dataset includes anonymized HPV typing results from
32,245 cervicovaginal samples from six studies of women aged 11
to 83 years conducted between 2001 through 2011 (Table 1).
Because all data were rendered non-identifiable before this
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analysis was conceived, the project does not involve human
subjects under United States Department of Health and Human
Services’ Code of Federal Regulations Title 45 Section 46.102(f).
All samples were from different immune-competent women in the
United States. The majority of samples were clinician collected
exfoliated cervical cells – 15,086 ThinPrepH (Hologic, Bedford,
MA, USA), 10,147 Specimen Transport MediumTM (Qiagen,
Valencia, CA); the remainder was self-collected cervicovaginal
specimens. Most specimens (28,417) were from screening or
general populations, but 3,828 were from colposcopy clinics. A
binary matrix of the HPV typing results with the general versus
colposcopy population status has been made available online (Data
S1).
HPV DNA Genotyping
All samples were extracted to yield DNA or total nucleic acids
(DNA and RNA), and 0.5–1% of the total sample extract was
tested for HPV. HPV typing was performed using the Linear
Array HPV Genotyping Test (LA, Roche Diagnostics, Indianap-
olis, IN) according to the manufacturer’s protocol. The LA detects
37 HPV types (6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51,
XR(52), 53, 54, 55, 56, 58, 59, 61, 62, 64, 66, 67, 68, 69, 70, 71,
72, 73, 81, 82, 83, 84, 89, IS39). HPV types 33, 35, and 58 have
type-specific probes, but HPV 52’s probe (XR) also reacts with
HPV 33, 35, and 58. Therefore when both a HPV 33, 35, or 58
probe and the XR probe is positive, the LA result is equivocal as to
whether HPV 52 is being detected or the probe is just reacting
with HPV 33, 35, or 58. Samples with equivocal results for HPV
52 were tested with a quantitative type-specific assay for HPV 52
[30]. All HPV DNA testing was conducted in a single laboratory
with rigorous quality control and high reproducibility.
HPV 56 and 66 Genotyping Specificity
In order to test the type specificity of the LA for HPVs 56 and
66, high copy numbers of their L1 genes were amplified from
plasmids. The primers were designed to flank the LA target region
(Table S1). Three different primer sets for each HPV type were
tested for efficiency of amplifying the target region and reproduc-
ibility of LA specificity. After PCR product quantification, 10 ul of
each amplicon was directly incorporated into the LA assay.
Statistical Analysis
Generating Expected Models. To determine the expected
number of concurrent infections, the matrix of observed results
was randomized in five different ways, depending on the
characteristics of the observed data being controlled, using R
(Figure 1 and Table S2) [31]. Observed data had rows by subject
and columns by 37 HPV types with zeros (0 s) indicating negative
HPV results and ones (1 s) indicating positive (Figure 1A). For the
null model of complete random association of HPV types in
Figure 1B, the 0 s and 1 s were shuffled within each column using
the ‘sample’ function of the R base package version 2.14.1,
preserving the count of each HPV type (fixed column sums) while
allowing the number of types per subject to vary (variable row
sums).
For the subsequent matrix randomizations, the ‘permatswap’
function created a series of matrix permutation models, each with
increasing fidelity to the real data, where some of the higher order
data structure is preserved during the randomization [32]. The
trial-swap method overcomes the deficiencies of other fixed
column/row sum algorithms in avoiding biased randomized
matrices [33]. The number of randomization steps was set to
56107 for the ‘burnin’ parameter as this value maximized Bray-
Curtis dissimilarity values, indicating effective matrix randomiza-
tion [33]. In the non-strata naı̈ve model, the matrix was
randomized while preserving the marginal HPV type counts and
types per person (fixed row and column sums; Figure 1C). For
higher fidelity randomization models, observations were stratified
based on the 6 studies (study strata), 1 through 14 concurrent
infections (k strata), or a combination of both (study-k strata) using
the ‘strata’ parameter of ‘permatswap’. Randomization within
each strata had fixed column and row sums (Figure 1D). To assess
general trends of concurrent infections, 10,000 randomized
matrices were generated from all the subjects (HPV positive and
negative) and compared to the expected results. To assess the
significance of specific type combinations, 1,000 randomized
matrices were generated from the HPV positive subjects and
analyzed as discussed below.
Calculating Statistics from Expected Models. Counting
occurrences of type combinations, whether in the observed data or
in the randomized matrices for a given model, was done in Perl
(Active Perl 5.8; ActiveState, Vancouver, BC). A key feature of the
counting, whether in observed or permuted data, was that specific
type combinations were counted whether or not additional types
were present. The results for the randomized matrices were then
matched to type combinations observed in the real data.
Results for the Perl scripts above were then read into a
Mathematica program to assess statistical significance (Wolfram
Research, Champaign IL). First, the expected counts of any given
type combination in the permutation models were fit to a Poisson
probability density function (pdf; Figure S1A). The Poisson
distribution fits were consistently very good (model p.0.99). To
graphically indicate significant type combinations, the observed
counts were compared to p-value boundaries created from the
Poisson distribution and the mean value parameter for each type
combination generated in the permutation models (recall a Poisson
distribution requires only the single parameter). Type combination
counts corresponding to p-value boundaries of 1024, 1026, 1028,
etc. were calculated for both the right (observed . expected) and
left (observed , expected) tails of the Poisson distribution.
Observed counts were then plotted against expected counts for a
given permutation model so that type combinations falling outside
the boundary value lines could be easily seen. Besides the
hypothetical p-value boundaries, actual p-values and Z-scores
were computed for each specific type combination using the
Poisson fit mean values from the permutation runs. Because the
type combination frequencies observed in the 1,000 randomized
matrices precisely fit a known and well characterized distribution,
p-values ,0.001 can be reliably estimated.
Due to the number of HPV type combinations analyzed, the
Benjamini and Hochberg false-discovery rate (fdr) was calculated
using ‘p.adjust’ in R to control for spurious results [34].
Further details on calculating the statistics are in Methods S1.
All code (R, Perl, or Mathematica) is available upon request.
Results
Of 32,245 subjects, 13,729 were positive for $1 HPV type, and
7,358 were positive for multiple HPV types (Table 1). Allowing for
the subset of individuals with multiple HPV types, specific HR
HPV types were detected 15,780 times out of a total of 28,666
HPV type positive results.
General Trends of Concurrent Infections
Figure 2A shows the results of testing the null model of complete
random association among HPV types as diagramed in Figure 1A
and B. The observed data did not overlap with the expected box
plot, indicating the observed concurrent infections of the aggregate
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dataset do not fit an unstructured random assortment. The box
heights in Figure 2A reveal that all of the 10,000 iterations of the
null expected model are highly self-consistent for the number of
HPV types per person and highly inconsistent with the real data.
At the maximum number of 9 expected HPV types per person in
the null model, only 2 people out of 3.226108 (3.226104 people/
iteration 6 16104 iterations) are expected to have this many
concurrent HPV types detected, whereas the observed data
contains a continuous distribution of subjects with up to 14
HPV types detected at the same time. Furthermore, infection with
0 and 3 through 14 HPV types occurred more than expected by
the null model. In contrast, infection with 1 and 2 HPV types
occurred less than expected.
Because such differences in general trends between the observed
data and null model would bias the analysis of specific HPV type
associations, these trends were preserved in subsequent random-
izations to create continuously less naı̈ve models. This random-
ization resulted in the distribution of each of the 10,000
permutation matrices exactly matching the observed results
(non-strata model; Figures 1C and 2B). However dividing the
data into 13 HR and 24 LR HPV types post-randomization shows
that the observed data has an additional level of structure which
may confound specific type analysis; the general distribution of
HR and LR HPV types differ between the observed and this first
permutation model (Figure S2A). Compared to this model, the
HR types are either alone or with 1 other HPV type more than
expected. Conversely, the LR types tend to have more observa-
tions in high numbers of concurrent infections than expected.
Grouping the dataset by studies, the differences in distribution
among HR and LR HPV types are blurred in the general
populations but increase further in the colposcopy populations
(Figure S2B and C). To control for this level of structure,
randomizations are conducted by conserving the type prevalence
and HPV types per person within each strata of HPV types per
person (k strata model; Figure 1D). In other words, data are
randomized separately within people with 2 types, people with 3
types, etc. This eliminates any difference in the distribution of HR
and LR HPV or even each specific HPV type k within strata
between the observed data and model. This method of stratifica-
tion removes 6,371 subjects with only 1 detected HPV type from
the concurrent infection analysis, and limits the analysis to the
7,358 subjects with $2 concurrent HPV types. Additionally data
are stratified by the study data source (study strata) and by
combined study and types per person (study-k strata). For this final
and least naı̈ve study-k model of the 84 possible strata (6 studies
614 k strata), 67 strata exist in the data as some studies do not
have all 14 k strata. For the study-k model, each observation of an
HPV type is restricted to potential interactions only with other
types of that stratum. The association among HPV types is still
randomized within these imposed structures.
Significant HPV Type Combinations
The permutation models were used to determine which specific
HPV type combinations are truly unexpected and which
combinations are artifacts of study factors structuring the dataset.
Figure 3 plots the observations for combinations of 2 through 4
HPV types for (A) the most naı̈ve model (the non-strata model with
only row and column sums preserved) and (B) the least naı̈ve
model (the study-k strata model). The significance boundary lines
for under observed type combinations bottom out on the right side
Figure 1. An abbreviated example of matrix randomizations. The observed data (A) of HPV infection status is organized in binary matrix
indicating type-specific infection status. To generate expected models, data are randomized while preserving column sums (null model; B) or row
and column sum (non-strata model; C). Additionally data were stratified by HPV types per person (k-strata model 2; D) or/and study data source
(study and study-k strata models; not shown) with randomization restricted to within each strata.
doi:10.1371/journal.pone.0082761.g001
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of the plot. This is because even zero observations of most 4 type
combinations can be expected and p = 0.0001 is difficult to achieve
even in a dataset of this size. The pairs with the largest positive and
negative Z-scores, 56 and 66 on the over observed side (left side of
Figure 3) and 16 and 72 on the under observed side (right side), are
indicated for illustration. Very few under observed 3 and 4 type
combinations were detected.
Table 2 lists HPV pairs observed more or less than expected in
the various models. As the general distribution of the null model in
Figure 2 differed so drastically from the observed results, a list of
significant specific type combinations for this model is uninfor-
mative and therefore not included. Of the permutation models, the
non-stratified model differs the most from the observed results, and
therefore finds the greatest number of HPV pairs to be significant
(47 pairs). However as additional levels of data structures are
conserved in the less naı̈ve models, fewer HPV pairs are
significant. Furthermore, only HPV pairs observed more than
expected passed the stringency test of the highest fidelity models;
no HPV pairs were significantly under observed against the k and
study-k models. However for the non-strata and study strata
models, vaccine-targeted type HPV 16 was found to be observed
less than expected with HPVs 58, 62, 69, 70, and 72. Several of
the HPV pairs observed more than expected were within the same
species. The association of HPVs 56 and 66 from species a6 has
the highest z-score compared to all models with a z-score
indicating at least 8 standard deviations away from the model
mean.
The data accommodate a more detailed scrutiny of multiple
concurrent infections. The significant results for 2, 3, and 4 type
combinations are interdependent (Tables 2A, S3, S4, and S5).
Although significantly over observed pairs like HPV types 56 and
66 pickup other types and therefore may drive the significance for
3 and 4 type combinations, the possibility remains that real
synergies exist between 3 or more types, or they appear to exist
because of cross-hybridizing types.
Because HPV 56 and 66 are strongly associated with each other
and are closely related genetically, it is important to exclude
artifacts of the assay that could account for the association. We
tested the specificity of the genotyping assay for these two types
using high copy numbers of type-specific templates. PCR
amplified HPV DNA only hybridized to the intended probe band
without cross hybridization (Figure S3).
Discussion
Observations from 6 different HPV genotyping studies were
combined to address whether concurrent HPV infections vary
from random assortment. Observations were compared with both
a null and progressively less naı̈ve models as row and column
sums, particular study, and concurrent infection burden variables
in the dataset were incorporated. The results of our null model are
consistent with other reports of multiple infections being detected
more than expected [21–25,27,28,35]. In our permutation models,
which incorporate restrictions based on the observed data
structure, certain specific HPV type combinations are statistically
significantly over or under observed. These models have greater
utility in testing the validity of alternative hypotheses and serve as a
more rigorous control than null models [36]. Additionally we have
demonstrated a novel approach to combine data from multiple
datasets that preserves statistical rigor while enhancing statistical
power.
Other groups have noted excess concurrent HPV type infections
compared to null models. The null hypotheses included maxi-
mum-likelihood based on an assumed Poisson distribution [35],
Hardy-Weinberg equilibrium test based calculation [23], simulat-
ing concurrent infections based on type frequencies in populations
[21,24], and Bayesian logistic regression [27,28]. These null
Figure 2. Differences between observed and expected number of people with concurrent infections. Dots representing observed
number of concurrent infections are plotted against boxplots of expected distribution from 10,000 randomized matrices. Boxplots indicate the
minimums and maximums, 25% and 75% quartiles, and medians of randomized matrices. (A) tests the null model of complete random association of
HPV types as in Figure 1B. (B) controls for observed types per person in the non-strata fixed margins permutation model as in Figure 1C. Note that
because the margins for all randomized matrices are set to be equal to that of the observed data and thus the same value for each permutation, the
‘‘boxes’’ have no ranges and are represented as single-value lines.
doi:10.1371/journal.pone.0082761.g002
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models demonstrate that HPV types are not distributed purely at
random in populations and are in agreement with the results using
our null model. Some women are infected with high numbers of
multiple HPV types and bear a disproportionate burden of HPV
types compared to the general population.
Some authors have controlled for risk factors of multiple HPV
infections while analyzing type-specific interactions. People
infected with HPV are more likely to acquire additional HPV
types than are uninfected persons [37]. Factors include age,
immunity, smoking, cervical pathology, lifetime number of sexual
partners, frequency of sexual intercourse, fidelity of sexual partner,
and study area.[8–16] Controlling for subsets of these factors has
reduced the discrepancies between the observed data and
expectations in various models [24,27,28]. However there are
limits in the ability to fully control for all known risk factors even if
they are measured, and the potential impact of unknown factors
cannot be addressed.
This current analysis takes a different approach to test HPV
type associations. The matrix permutation models presented in
this manuscript are based on recommendations as discussed by
Schwab, et al. [36]. Our models do not incorporate knowledge
about underling processes or confounding factors for multiple
HPV infections. They attempt a more rigorous challenge than the
null model by randomizing the data within basic data structure
restrictions. By fixing row sums and stratifying on k-strata, the
number of HPV types per person is accounted for regardless of
knowing or not knowing the prevalence of risk factors for multiple
HPV infections in the study populations. This increases the
number of suitable datasets. Instead of being restricted to data in
which at least most of the risk factors are recorded, all datasets
with sound laboratory assays of type-specific HPV results are
applicable. The tested HPV types can even vary among the
studies.
Another limitation of the previous work is the restriction of each
analysis to single study datasets. Prior studies have relatively small
specimen numbers compared to the number of possible HPV
combinations. Often, HPV testing was performed for a small
subset of genital HPV types. Even with multiple HPV types
assayed, because of small sample size, statistical analysis was
limited to a few HPV types. In the largest previous study with
13,961 women, only 1,451 were HPV positive [27]. In contrast
our current dataset has 13,729 HPV positive subjects of which
7,358 are positive for multiple HPV types. While combining
multiple datasets results in greater statistical power due to
increased sample size, the heterogeneity of the aggregated studies
is a complicating factor. The studies in our analysis varied by
population, collection method, and target tissue. A model
randomized across studies increases the risk of type I error. We
address this issue by stratifying the aggregate dataset by study and
confining the randomization to within each stratum. Consistent
with weeding out type I errors, significant type combinations were
reduced in the study strata model compared to the non-strata
model.
Figure 3. Significant combinations for k = two, three and four HPV types. The graphs depict the non-strata (A) and study-k (B) permutation
models. Boundary lines (dots) show p-value significance at 1024 and 1028. The mean expected counts on the x-axis represents the average number
of observations from 1,000 randomized matrices; the y-axis shows the actual observed counts for the type combinations. Single observations of 4
HPV type combinations are excluded.
doi:10.1371/journal.pone.0082761.g003
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Table 2. Significant HPV Pairs.
A Observed/Expected (Z-score) for Models.
HPV Types* Species Observations Non-Strata Study Strata k Strata Study-k Strata
56,66 a6, a6 164 2.2 (10.4) 2.1 (9.9) 1.8 (8.0) 1.9 (8.1)
51,82 a5, a5 65 2.0 (5.5) 2.0 (5.6) 1.8 (4.9) 1.8 (4.8)
51,69 a5, a5 20 3.0 (5.2) 2.9 (5.0) 2.7 (4.7) 2.8 (4.8)
33,58 a9, a9 38 2.0 (4.5) 1.7 (3.2) 2.2 (5.0) 2.0 (4.3)
52,58 a9, a9 129 1.5 (4.8) 1.4 (4.0) 1.5 (5.0) 1.4 (4.0)
51,IS39 a5, a5 18 2.9 (4.7) 2.7 (4.4) 2.2 (3.4) 2.2 (3.4)
16,18 a9, a7 194 1.3 (3.7) 1.3 (3.3)
31,45 a9, a7 75 1.5 (3.3) 1.5 (3.3)
62,83 a3, a3 110 1.4 (3.7) 1.4 (3.2) 1.4 (3.5) 1.4 (3.2)
55,62 a10, a3 82 1.6 (4.2) 1.5 (3.6) 1.5 (3.6) 1.4 (3.1)
81,83 a3, a3 57 1.6 (3.5) 1.6 (3.5) 1.5 (3.0)
62,81 a3, a3 84 1.5 (3.8) 1.5 (4.0)
71,72 a15, a3 11 2.6 (3.2) 3.2 (4.0)
72,83 a3, a3 29 1.7 (2.8) 1.9 (3.6)
61,62 a3, a3 133 1.3 (3.4) 1.4 (3.5)
62,70 a3, a7 63 1.5 (3.4)
61,70 a3, a7 54 1.6 (3.3)
61,83 a3, a3 90 1.4 (3.3) 1.4 (3.0)
70,72 a7, a3 15 2.1 (2.9)
71,83 a15, a3 22 1.9 (2.9) 1.8 (2.8)
67,84 a9, a3 64 1.4 (2.8)
62,72 a3, a3 35 1.6 (2.8)
61,71 a3, a15 24 1.7 (2.8)
16,39 a9, a7 224 1.2 (2.7)
66,89 a6, a3 137 1.4 (3.7) 1.3 (3.5)
6,89 a10, a3 99 1.4 (3.0) 1.4 (3.1)
51,66 a5, a6 161 1.3 (3.3) 1.3 (3.0)
35,83 a9, a3 67 1.5 (3.1)
54,61 a13, a3 108 1.3 (3.0)
11,18 a10, a7 21 1.9 (3.0)
42,56 a1, a6 78 1.4 (2.9)
26,35 a5, a9 13 2.2 (2.9)
42,73 a1, a11 55 1.5 (2.8)
B Observed/Expected (Z-score) for Models
HPV Types* Species Observations Non-Strata Study Strata k Strata Study-k Strata
16,58 a9, a9 109 0.7 (23.1) 0.7 (23.9)
16,72 a9, a3 23 0.4 (24.1) 0.5 (23.7)
31,62 a9, a3 63 0.6 (23.8) 0.7 (23.3)
58,59 a9, a7 40 0.6 (23.3) 0.6 (23.3)
66,70 a6, a7 23 0.5 (23.1) 0.5 (23.1)
66,72 a6, a3 10 0.4 (23.0) 0.4 (23.1)
16,62 a9, a3 175 0.7 (24.0) 0.8 (22.9)
16,70 a9, a7 58 0.6 (23.5) 0.7 (22.9)
39,83 a7, a3 44 0.6 (23.4) 0.7 (22.9)
51,72 a5, a3 14 0.5 (22.9) 0.5 (22.9)
31,83 a9, a3 42 0.6 (22.9) 0.6 (22.8)
16,69 a9, a5 2 0.2 (22.8) 0.2 (22.8)
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The approach we used gives greater confidence in interpreting
the biologic significance of the identified type associations. Pairs of
HPV types detected more frequently than expected were often
from the same species [38]. HPVs 56 and 66 are from species a6.
HPVs 51, 69, 82, and IS39 are all from species a5, and IS39 is
considered a subtype of HPV 82. Finally HPVs 33, 35, 52, and 58
are part of a9. Probes for HPV 52 are known to cross hybridize
with HPVs 33, 35, and 58. Vaccarella et al. also found positive
association among a9 types 33, 35, 52, and 58, but attributed this
to the ambiguity of HPV 52 in the enzyme immunoassay [27] and
line blot assay [28]. For the line blot assay used for our data,
whenever the HPV 52 probe and any of these other 3 probes are
positive, the line blot assay is ambiguous for detection of HPV 52.
Our studies used a subsequent type-specific PCR assay for HPV
52 to eliminate the ambiguity in these situations. Because of the
genetic similarity within species, the limits of type-specificity in
consensus PCR assays (such as LA) due to cross-hybridization
could be suspected. However all results were obtained under
stringent quality control, and high copy numbers of HPV 56 and
66 DNAs did not cross hybridize. Uncharacterized HPV types that
produce amplicons that hybridize to multiple probes cannot be
completely ruled out but are very unlikely because of the design of
the assay and previous validation studies. Positive associations
among HPV types were also found between non-species types.
The significant type combinations likely indicate a genuine
association among the above species types.
Fewer and less significant negative associations among HPV
types were identified. No pairs of HPV types passed the statistical
cutoffs for the stringent k strata and study-k strata models, and no
negative associations for any model were found for combinations
of 3 and 4 types. HPV 16 was frequently included as one of the
types of pairs observed less frequently than expected in the non-
strata and study strata models. The types observed less frequently
than expected with HPV 16 are candidates for type replacement
following reduction of HPV 16 by vaccination. The only HR type
in this group was HPV 58; most negative associations with HPV
16 were with LR types. A nonavalent HPV vaccine in clinical trials
is formulated to target HPV 6, 11, 16, 18, 31, 33, 45, 52 and 58,
and thus HPV 58 would be targeted and at reduced risk of
replacing HPV 16. Also, the study strata model indicates a possible
negative association between HR types 58 and 59. However no
negative associations were significant against the least naı̈ve
models, reducing the probability of type replacement.
A strength of the implemented method is that distribution
functions were tightly fit to the permutated data to accurately
calculate p-values. Typically for permutated data, p-values can
only be calculated down to the inverse of the number of
permutations. If a HPV combination does not occur even once
at of 1000 permutations, the p-value would be ,0.001. However
because a distribution function can be fit to the permutated data,
we can calculate p-values below the permutation limit. Thus p-
values down to 1028 and smaller can be calculated without
needing 108 permutations. This allows accurate significance
testing while conserving computer resources.
Limitations exist with the current analysis. The contribution of
each study to the analysis is proportional to the sample size of each
study. Thus larger studies contribute more to the final results. A
weighting factor for each study stratum would adjust this. We
suggest that imposing the structure of the observed data in terms of
column and row sums, and stratification, controls for the risk
factors of multiple HPV types, e.g. risk factors for increasing HPV
exposure. However without these variables in the dataset, this
proposition cannot be tested directly.
The methodology presented can be applied to other data.
Indeed, the current analysis is an expansion of a previous
application. This randomization within strata was first used to
test species’ associations on archipelago islands [29]. By stratifying
the dataset prior to randomization within the strata, it relaxes the
analyst from making assumptions about the null distribution of the
data and having information available on risk factors. By
stratifying on studies, this methodology may be adapted to
prospectively analyzing data from meta-anaylsis studies.[39] The
presented analysis consisted of a binary matrix, however the
algorithms used can be applied to other data types, expanding its
application [32].
We have presented a novel approach to HPV concurrent
infection analysis, which has allowed us to obtain greater statistical
Table 2. Cont.
B Observed/Expected (Z-score) for Models
HPV Types* Species Observations Non-Strata Study Strata k Strata Study-k Strata
53,81 a6, a3 45 0.7 (22.8)
16,83 a9, a3 113 0.7 (23.2)
16,84 a9, a3 190 0.8 (23.0)
67,83 a9, a3 14 0.5 (22.9)
16,55 a9, a10 72 0.7 (22.9)
31,70 a9, a7 21 0.5 (22.9)
16,71 a9, a15 19 0.5 (22.9)
39,62 a7, a3 83 0.7 (22.8)
39,81 a7, a3 33 0.6 (22.7)
39,84 a7, a3 84 0.7 (22.7)
39,70 a7, a7 26 0.6 (22.7)
16,61 a9, a3 157 0.8 (22.7)
Results are listed for HPV pairs with fdr #0.05 for (A) observed more than expected and (B) observed less than expected.
*HR-HPV types are underlined.
doi:10.1371/journal.pone.0082761.t002
Modeling Concurrent HPV Infections
PLOS ONE | www.plosone.org 8 December 2013 | Volume 8 | Issue 12 | e82761
power to address the question of HPV type association as well as
provide new methods to analyze aggregate datasets.
Supporting Information
Figure S1 Illustration of how 1000 randomized matrices
are used to determine significance boundaries shown in
Figure 2. Example (A) of a Poisson probability density function fit
to the observed counts for a given type combination in 100
iterations of a permutation model Monte Carlo randomization.
The plot (B) shows the number of observations needed to meet
p = 0.0001 significance (y-axis) vs. number expected by a given
permutation model (x-axis). The x-axis corresponds to the mean
number of counts observed in the 1000 Monte Carlo runs from any
of the models. The equation embedded shows the power law fit used
to create the boundary value lines on the left side of the plot (i.e. over
observed type combinations) in Figure 3. The fits describe the right
tail of the Poisson pdf (the number of observations needed to match
the level of significance) fit to the mean number of observations for
any given type combination in the Monte Carlo runs. For example,
if 28 = 256 counts are expected in the given permutation model,
then roughly 340 observations in the real data are needed to satisfy
p = 0.0001. If only 16 counts are expected, the needed number
observed counts increases (as a ratio relative to expected) to about
40 for the same level of significance. Rarely observed type
combinations with very rare expected values in the permutation
models (i.e. candidates for over observed combinations, not under
observed) were excluded from the analysis of significance. This is
because, for example, it is difficult to determine the true significance
or impact of a 4 type combination that is seen in the observed data
only once, even if it was expected ,0.001 times (for a very large
observed/expected ratio) in a database of 30,000 specimens.
(TIF)
Figure S2 Difference between the observed data and the
10,000 non-strata model segregated by high-risk and
low-risk HPV types: all subjects (A), general population (B),
colposcopy population (C).
(TIF)
Figure S3 Testing specificity of HPV DNA genotyping
test on PCR amplified plasmid DNA for (A) HPV 56 and (B) 66.
(TIF)
Table S1 Primer sequences used for HPV 56 and 66
PCR amplification.
(DOC)
Table S2 Key parameters and assumptions of the
different randomization models.
(DOC)
Table S3 Significant 3 HPV type combinations.
(DOC)
Table S4 Significant 4 HPV type combinations.
(DOC)
Table S5 Number of times HPV types appeared in
significant combinations.
(DOC)
Methods S1 Supplementary methods for statistical
calculations.
(DOC)
Data S1 Supplementary data.
(TXT)
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